---
title: "ACRV.US (ACRV.US) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/ACRV.US/news.md"
symbol: "ACRV.US"
name: "ACRV.US"
parent: "https://longbridge.com/zh-HK/quote/ACRV.US.md"
datetime: "2026-03-14T14:50:47.313Z"
locales:
  - [en](https://longbridge.com/en/quote/ACRV.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ACRV.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ACRV.US/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/ACRV.US/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/ACRV.US/news.md)


# ACRV.US (ACRV.US) — 相關新聞

### [Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer](https://longbridge.com/zh-HK/news/277229029.md)
*2026-02-27T16:47:49.000Z*
> Acrivon Therapeutics hosted a webcast discussing the ACR-368 Phase 2B study in serous endometrial cancer, highlighting a

### [Acrivon Therapeutics presents interim ACR-368 Phase 2b data showing activity in serous endometrial cancer](https://longbridge.com/zh-HK/news/277211854.md)
*2026-02-27T14:03:00.000Z*
> Acrivon Therapeutics presented interim Phase 2b data for ACR-368, highlighting its effectiveness in serous endometrial c

### [04:00 ETNucleome Therapeutics appoints experienced biotech executive Dr. Michelle Morrow as Chief Scientific Officer](https://longbridge.com/zh-HK/news/276045179.md)
*2026-02-16T09:00:38.000Z*
> Nucleome Therapeutics has appointed Dr. Michelle Morrow as Chief Scientific Officer, effective February 23, 2026. Dr. Mo

### [Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Drop in Short Interest](https://longbridge.com/zh-HK/news/275603665.md)
*2026-02-11T12:21:18.000Z*
> Acrivon Therapeutics, Inc. (NASDAQ:ACRV) experienced a significant drop in short interest, falling 73.1% from 7,521,144 

### [Avacta Therapeutics hires Francis Wilson as Chief Scientific Officer, specializing in oncology delivery platform PreCISION®.](https://longbridge.com/zh-HK/news/275278299.md)
*2026-02-09T07:01:45.000Z*
> In a recent announcement on February 9, 2026, Avacta Therapeutics (AIM: AVCT), a leading biopharmaceutical company based

### [Acrivon Therapeutics to present Phase 2b study data on ACR-368 for endometrial cancer at ESGO Congress by Dr. Konstantinopoulos.](https://longbridge.com/zh-HK/news/273521235.md)
*2026-01-23T13:14:07.000Z*
> Renowned expert Dr. Panagiotis Konstantinopoulos from Dana-Farber Cancer Institute will present recent interim clinical 

### [Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress | ACRV Stock News](https://longbridge.com/zh-HK/news/273520305.md)
*2026-01-23T05:11:00.000Z*
> Acrivon Therapeutics announced a late-breaking oral presentation at the ESGO Annual Congress, scheduled for February 26-

### [3 Best Stocks to Buy Today, 1/22/2026, According to Top Analysts](https://longbridge.com/zh-HK/news/273377650.md)
*2026-01-22T13:02:51.000Z*
> Top Wall Street Analysts recommend three stocks as Strong Buys: Rigetti Computing (RGTI) with a price target of $35, imp

### [Avacta Announces US FDA Clearance Of The Investigational New Drug Application For The Second pre|CISION Medicine, FAP-Exatecan](https://longbridge.com/zh-HK/news/273234257.md)
*2026-01-21T13:05:35.000Z*